Not Yet Recruiting PHASE2 INTERVENTIONAL 2-arm
NCT07393438
Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS) (AHA-PLUS)
Acetohydroxamic Acid Combined With a Short-Course Regimen for the Treatment of Multidrug-Resistant Tuberculosis: A Phase II Clinical Trial
Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Interventions
Acetohydroxamic Acid Placebo
Updated 1 time since 2026 Last updated: Jan 31, 2026 Started: Feb 21, 2026 Primary completion: Feb 28, 2027 Completion: Nov 30, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE2 clinical study on MDR-TB and Multidrug-Resistant Tuberculosis, this trial is actively recruiting participants. The trial is conducted by Shanghai Pulmonary Hospital, Shanghai, China and has accumulated 1 data snapshot since 2026. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Shanghai Pulmonary Hospital, Shanghai, China
Data source: Shanghai Pulmonary Hospital, Shanghai, China
For direct contact, visit the study record on ClinicalTrials.gov .